Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5902611 | 0.82 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL5902134 | 0.82 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL44909 | 0.76 | ALDH1A1 (0.36) | FFAR3ALDH1A1TDP1 | |
| SCHEMBL109778 | 0.76 | ALDH1A1 (0.36) | FFAR3ALDH1A1TDP1 | |
| Acetic Acid SCHEMBL6238297 | 0.74 | FFAR3 (0.35) | FFAR3ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL5177423 | 0.74 | ALDH1A1 (0.35) | FFAR3ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL27756695 | 0.74 | ALDH1A1 (0.35) | FFAR3ALDH1A1TDP1 | |
| SCHEMBL23428438 | 0.73 | ALDH1A1 (0.38) | FFAR3ALDH1A1TDP1 | |
| Chloromethane SCHEMBL219837 | 0.73 | ALDH1A1 (0.33) | FFAR3ALDH1A1TDP1 | |
| Hydrochloric Acid SCHEMBL10569852 | 0.73 | FFAR3 (0.33) | FFAR3ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11998532-B1 | Substituted 1,3,4-oxadiazole derivatives as anti-tubercular agents | King Faisal University (SA) | 2024-06-04 | — | — | US | disclosed |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| EP-3807254-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | Epigen Biosciences, Inc. (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2020114482-A1 | ISOINDOLINE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND APPLICATION OF ISOINDOLINE COMPOUND | 中国科学院上海药物研究所 | 2020-06-11 | — | — | WO | disclosed |
| EP-1937652-B1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMA INC (US) | 2014-07-30 | — | — | EP | disclosed |
| CN-101538246-B | Pyrimidine amide compounds as PGDS inhibitors | AVENTIS PHARMA INC | 2014-07-16 | — | — | CN | disclosed |
| US-8202863-B2 | 2-Phenyl-pyrimidine-5-carboxylic acid benzylamide; to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease | AVENTIS PHARMACEUTICALS INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2008-09-18 | — | — | US | disclosed |
| EP-1937652-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007041634-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227782-A1 | PYRIMIDINE AMIDE COMPOUNDS AS PGDS INHIBITORS | HRH2, HRH1, LTC4S | FFAR3 1223/4885ALDH1A1 871/4885TDP1 1567/4885 |
| US-11998532-B1 | Substituted 1,3,4-oxadiazole derivatives as anti-tubercular agents | OXA1L, DUT, TALDO1 | FFAR3 4034/4885ALDH1A1 483/4885TDP1 1584/4885 |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR2, LPAR4 | FFAR3 99/4885ALDH1A1 2298/4885TDP1 2700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.